Abstract |
H. pylori is regarded as a primary etiologic factor in gastric disease and the therapies now include a combination of antimicrobial agents with antiulcer drugs. Here, the effect of a new gastroprotective agent, sulglycotide, on the in vitro anti-H. pylori activity of metronidazole, erythromycin, tetracycline, and amoxycillin was assessed. The assays in the absence of sulglycotide gave MIC value 0.10mg/L for erythromycin, 0.12mg/L for amoxycillin, 0.15mg/L for tetracycline and 14mg/L for metronidazole, while sulglycotide alone gave MIC value of 20mg/L. The sulglycotide at its optimal dose (5mg/L) evoked a 4-fold enhancement in the MIC of amoxycillin, 5-fold in tetracycline, and 8.3-fold in erythromycin, while the MIC of metronidazole improved 3.5-fold at 10mg/L sulglycotide. The results point towards the advantage of combination therapy of sulglycotide and antibiotics for H. pylori eradication.
|
Authors | J Piotrowski, V L Murty, A Slomiany, B L Slomiany |
Journal | Biochemistry and molecular biology international
(Biochem Mol Biol Int)
Vol. 35
Issue 3
Pg. 467-72
(Mar 1995)
ISSN: 1039-9712 [Print] England |
PMID | 7773183
(Publication Type: Journal Article)
|
Chemical References |
- Sialoglycoproteins
- Metronidazole
- sulglicotide
- Erythromycin
- Amoxicillin
- Tetracycline
|
Topics |
- Amoxicillin
(pharmacology)
- Erythromycin
(pharmacology)
- Helicobacter pylori
(drug effects)
- Metronidazole
(pharmacology)
- Microbial Sensitivity Tests
- Sialoglycoproteins
(pharmacology)
- Tetracycline
(pharmacology)
|